- Home
- PAX vs SUPN Comparison
PAX vs SUPN Comparison
Compare PAX & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAX
- SUPN
- Stock Information
- Founded
- PAX 1988
- SUPN 2005
- Country
- PAX Cayman Islands
- SUPN United States
- Employees
- PAX N/A
- SUPN N/A
- Industry
- PAX Investment Managers
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- PAX Finance
- SUPN Health Care
- Exchange
- PAX Nasdaq
- SUPN Nasdaq
- Market Cap
- PAX 2.3B
- SUPN 2.6B
- IPO Year
- PAX 2021
- SUPN 2012
- Fundamental
- Price
- PAX $14.47
- SUPN $45.46
- Analyst Decision
- PAX Strong Buy
- SUPN Buy
- Analyst Count
- PAX 1
- SUPN 2
- Target Price
- PAX $14.00
- SUPN $43.00
- AVG Volume (30 Days)
- PAX 555.6K
- SUPN 638.4K
- Earning Date
- PAX 11-04-2025
- SUPN 11-03-2025
- Dividend Yield
- PAX 6.04%
- SUPN N/A
- EPS Growth
- PAX N/A
- SUPN 1411.53
- EPS
- PAX 0.53
- SUPN 1.14
- Revenue
- PAX $397,504,000.00
- SUPN $665,125,000.00
- Revenue This Year
- PAX N/A
- SUPN $4.84
- Revenue Next Year
- PAX $22.27
- SUPN $17.69
- P/E Ratio
- PAX $27.42
- SUPN $40.79
- Revenue Growth
- PAX 26.52
- SUPN 5.55
- 52 Week Low
- PAX $9.43
- SUPN $29.16
- 52 Week High
- PAX $14.58
- SUPN $46.79
- Technical
- Relative Strength Index (RSI)
- PAX 70.27
- SUPN 64.24
- Support Level
- PAX $13.29
- SUPN $45.26
- Resistance Level
- PAX $14.58
- SUPN $46.72
- Average True Range (ATR)
- PAX 0.27
- SUPN 1.04
- MACD
- PAX 0.11
- SUPN -0.24
- Stochastic Oscillator
- PAX 92.09
- SUPN 55.96
About PAX Patria Investments Limited
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.